James Mulheron has accepted a one-year suspension from USADA for an anti-doping violation stemming from an out-of-competition sample collected on Nov. 10.
The UFC announced the heavyweight’s sanction in a statement on Tuesday:
Mulheron, 29, tested positive for clomiphene and its metabolite, hydroxyclomiphene, following an out-of-competition urine test conducted on November 10, 2017. Clomiphene is a Specified Substance in the class of Hormone and Metabolic Modulators and is prohibited at all times under the UFC Anti-Doping Policy, which has adopted the World Anti-Doping Agency Prohibited List.
Clomiphene is not approved by the U.S. Food & Drug Administration (FDA) or the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) for use in the male population, as its use has not been thoroughly studied for safety and efficacy. Clomiphene also indirectly promotes the secretion of testosterone. Increasing testosterone, especially when combined with strength training, has been demonstrated to increase fat-free mass, muscle size, and strength in males, potentially leading to performance enhancement in sport.
Mulheron’s one-year period of ineligibility began on November 17, 2017, the date his provisional suspension was imposed. As a result of his positive test, Mulheron was removed from the Card for the UFC Fight Night event in Shanghai, China, scheduled for November 25, 2017.
Mulheron made his Octagon debut at UFC Fight Night 113, where he suffered a unanimous decision loss to Justin Willis on July 16. “The Juggernaut” owns an 11-2 career record that also includes a win over Neil Grove under the Bellator MMA banner.